Irbesartan Eg (Irbesartan)

Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on blood vessels and adrenal glands. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone release, leading to relaxed blood vessels, reduced sodium and water retention, and ultimately lower blood pressure and decreased strain on the heart and kidneys.

The appropriate dose of Irbesartan Eg is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and kidney function. Dosage adjustments may be needed for elderly patients or those with renal impairment, and the prescriber will provide specific instructions.

Irbesartan is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy, especially in the second and third trimesters. Limited data are available for breastfeeding; therefore, the drug is generally avoided while nursing unless the benefits outweigh the potential risks.

To request Irbesartan Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Irbesartan belongs to the angiotensin II receptor blocker (ARB) class, offering similar blood‑pressure reduction to other ARBs such as losartan but with a slightly longer half‑life and once‑daily dosing for many patients. Compared with ACE inhibitors, ARBs like Irbesartan have a lower incidence of cough and angio‑edema, making them a preferred option for patients who cannot tolerate ACE inhibitors.

Irbesartan Eg should be stored below 25 °C in a dry place. Keep the product in its original packaging to protect it from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Irbesartan Eg is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and should not crush or split the tablet unless advised.

The most serious adverse events to monitor are hyperkalemia (high potassium), acute kidney injury, and angio‑edema, which can be life‑threatening. Patients should report sudden swelling of the face, lips, tongue, or difficulty breathing, as well as marked weakness, irregular heartbeat, or a rapid rise in serum creatinine.

Irbesartan Eg is contraindicated in patients with known hypersensitivity to Irbesartan or any component of the formulation, in pregnant women, and in individuals with bilateral renal artery stenosis. Caution is also advised for patients with severe hepatic impairment or those taking other potent RAAS inhibitors.